We serve Chemical Name:[(3R)-1-benzylpyrrolidin-3-yl]methanamine CAS:229323-04-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![[(3R)-1-benzylpyrrolidin-3-yl]methanamine](https://a.dearchem.com/CAS2/229323-04-0.png)
Chemical Name:[(3R)-1-benzylpyrrolidin-3-yl]methanamine
CAS.NO:229323-04-0
Synonyms:(R)-(1-Benzylpyrrolidin-3-yl)methylamine;(3R)-3-Aminomethyl-1-benzylpyrrolidine;3-Pyrrolidinemethanamine,1-(phenylmethyl)-,(3R)
Molecular Formula:C12H18N2
Molecular Weight:190.28500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:284.3ºC at 760mmHg
Density:1.04g/cm3
Index of Refraction:1.563
PSA:29.26000
Exact Mass:190.14700
LogP:2.10540
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (R)-(1-Benzylpyrrolidin-3-yl)methylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Pyrrolidinemethanamine,1-(phenylmethyl)-,(3R) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Pyrrolidinemethanamine,1-(phenylmethyl)-,(3R) Use and application,(3R)-3-Aminomethyl-1-benzylpyrrolidine technical grade,usp/ep/jp grade.
Related News: When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. [(3R)-1-benzylpyrrolidin-3-yl]methanamine manufacturer The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. [(3R)-1-benzylpyrrolidin-3-yl]methanamine supplier Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis. [(3R)-1-benzylpyrrolidin-3-yl]methanamine vendor Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis. [(3R)-1-benzylpyrrolidin-3-yl]methanamine factory The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. [(3R)-1-benzylpyrrolidin-3-yl]methanamine manufacturer The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. [(3R)-1-benzylpyrrolidin-3-yl]methanamine supplier Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis. [(3R)-1-benzylpyrrolidin-3-yl]methanamine vendor Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis. [(3R)-1-benzylpyrrolidin-3-yl]methanamine factory The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease.
